{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:28:20Z","timestamp":1789410500734,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chief Scientist Office of the Ministry of Health, Israel","award":["3-0000-14861"],"award-info":[{"award-number":["3-0000-14861"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: The rise of multi-drug-resistant pathogens and nosocomial infections among hospitalized patients is partially attributed to the increased use of antibiotic therapy. A prediction model for in-hospital antibiotic treatment could be valuable to target preventive strategies. Methods: This was a retrospective cohort study, including patients admitted in 2018 to medical departments and not treated with antibiotics during the first 48 h. Data available at hospital admission were used to develop a logistic model to predict the probability of antibiotic treatment during hospitalization. The performance of the model was evaluated in two independent validation cohorts. Results: In the derivation cohort, antibiotic treatment was initiated in 454 (8.1%) out of 5592 included patients. Male gender, lower functional capacity, prophylactic antibiotic treatment, medical history of atrial fibrillation, peripheral vascular disease, solid organ transplantation, chronic use of a central venous catheter, urinary catheter and nasogastric tube, albumin level, mental status and vital signs at presentation were identified as predictors for antibiotic use during hospitalization and were included in the prediction model. The area under the ROC curve (AUROC) was 0.72 (95% CI 0.70\u20130.75). In the highest probability group, the percentage of antibiotic treatment was 18.2% (238\/1,307). In the validation cohorts, the AUROC was 0.73 (95% CI 0.68\u20130.77) and 0.75 (95% CI 0.72\u20130.78). In the highest probability group, the percentage of antibiotic treatment was 12.5% (66\/526) and 20.7% (244\/1179) of patients. Conclusions: Our prediction model performed well in the validation cohorts and was able to identify a subgroup of patients at high risk for antibiotic treatment.<\/jats:p>","DOI":"10.3390\/antibiotics11060813","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:48:12Z","timestamp":1655430492000},"page":"813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting In-Hospital Antibiotic Use in the Medical Department: Derivation and Validation Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-7413","authenticated-orcid":false,"given":"Itamar","family":"Poran","sequence":"first","affiliation":[{"name":"Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Elbaz","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Turjeman","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maayan","family":"Huberman Samuel","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Eliakim-Raz","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-018X","authenticated-orcid":false,"given":"Jeries","family":"Nashashibi","sequence":"additional","affiliation":[{"name":"Department of Medicine D, Rambam Health Care Campus, Haifa 3436212, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Rambam Health Care Campus, Haifa 3436212, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3436212, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e187571","DOI":"10.1001\/jamanetworkopen.2018.7571","article-title":"Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals","volume":"2","author":"Rhee","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2017.13836","article-title":"CDC Prevention Epicenter Program Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009\u20132014","volume":"318","author":"Rhee","year":"2017","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data","volume":"14","author":"Gandra","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1473-3099(20)30332-7","article-title":"Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000\u20132015: An analysis of pharmaceutical sales data","volume":"21","author":"Klein","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team Prevalence of antimicrobial use in US acute care hospitals, May-September 2011","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","unstructured":"(2021, June 08). WHO Global Action Plan on Antimicrobial Resistance. Available online: http:\/\/www.wpro.who.int\/entity\/drug_resistance\/resources\/global_action_plan_eng.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"vi17","DOI":"10.1093\/jac\/dky115","article-title":"Variation in antibiotic use among and within different settings: A systematic review","volume":"73","author":"Zanichelli","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10096-018-3434-0","article-title":"How to measure quantitative antibiotic use in order to support antimicrobial stewardship in acute care hospitals: A retrospective observational study","volume":"38","author":"Kallen","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jac\/dkw454","article-title":"Variability in antibiotic use across Ontario acute care hospitals","volume":"72","author":"Tan","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14787210.2015.1040766","article-title":"Antibiotic use in US hospitals: Quantification, quality measures and stewardship","volume":"13","author":"Reddy","year":"2015","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. the index of ADL: A standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(19)31785-4","article-title":"Management of frailty: Opportunities, challenges, and future directions","volume":"394","author":"Dent","year":"2019","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"786.e1","DOI":"10.1016\/j.cmi.2015.04.005","article-title":"Identification of patients at high risk for Clostridium difficile infection: Development and validation of a risk prediction model in hospitalized patients treated with antibiotics","volume":"21","author":"Jajou","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","article-title":"Clostridium difficile infection: Review","volume":"38","author":"Czepiel","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/JLP.JLP_106_18","article-title":"Evaluation of various risk factors associated with multidrug-resistant organisms isolated from diabetic foot ulcer patients","volume":"11","author":"Datta","year":"2019","journal-title":"J. Lab. Physicians"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jgar.2019.09.006","article-title":"Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: A meta-analysis","volume":"21","author":"Li","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.cmi.2015.03.024","article-title":"Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: Focus on skin and soft-tissue infections","volume":"21","author":"Dryden","year":"2015","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:33:32Z","timestamp":1760139212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["antibiotics11060813"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11060813","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}